NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 94.1% from a year ago
Common stock stood at $33K at the end of Q1 FY2026, up 94.1% from a year earlier and up 3.1% from the prior quarter. Over 3 fiscal years it compounded at -21.8% a year.
Context
- Common stock amounted to 0.3% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +94.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 32K USD
- Year-over-year change
- +113.3%
- 4-year CAGR
- -14.2%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32K | +113.3% |
| FY2024 | 2024-12-31 | 15K | -82.1% |
| FY2023 | 2023-12-31 | 84K | +25.4% |
| FY2022 | 2022-12-31 | 67K | +13.6% |
| FY2021 | 2021-12-31 | 59K | — |
Common Stock vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 common stock of $33K is the 2nd highest of the 9 companies compared; the peer median is $5K.
- Its year-over-year change of +94.1% is the 4th highest of 9, against a peer median of +37.2%.
- Common stock amounts to 0.3% of total assets for NRXP, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.05M | +217.9% | -38.1% | 4.8% | |
| Mar 2026 | $33K | +94.1% | -21.8% | 0.3% | |
| Mar 2026 | $18K | +100.0% | +14.5% | 0.0% | |
| Mar 2026 | $14K | +7.7% | +5.3% | 0.0% | |
| Mar 2026 | $5K | +66.7% | +18.6% | 0.0% | |
| Jun 2026 | $5K | +0.0% | +18.6% | 0.0% | |
| Mar 2026 | $3K | -95.2% | +31.1% | 0.0% | |
| Mar 2026 | $656 | +94.7% | -33.5% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding NRXP) | $5K | +37.2% | +14.5% | 0.0% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.